NXGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nexgel Inc (NXGL) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has bearish technical indicators, and its financial performance shows declining revenue and negative net income. While analysts maintain a Buy rating, the reduced price target and lack of recent trading signals suggest it is better to hold off on investing in this stock for now.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 49.061, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 0.655, with key resistance at 0.739 and support at 0.571. Overall, the technical indicators do not suggest a strong buy opportunity.
The company's acquisition of Celularity has the potential to transform NexGel into a profitable entity in the future. Analysts maintain a Buy rating despite lowering the price target.
The stock lacks significant trading trends among hedge funds and insiders. No recent news or congress trading data is available. Reduced price target from $6 to $2 reflects dilution concerns.
In Q4 2025, revenue dropped by 8.06% YoY to $2,796,000. Net income improved slightly but remains negative at -$970,000, up 14.12% YoY. EPS stayed flat at -0.12. Gross margin improved to 29.29%, up 14.32% YoY, but overall financials indicate weak performance.
Maxim lowered the price target from $6 to $2 while maintaining a Buy rating. The adjustment reflects dilution concerns related to the financing for the Celularity acquisition.
